NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis 1.57 -0.03 (-1.88%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range1.46▼1.6350-Day Range1.57▼5.9052-Week Range1.46▼441.70Volume75,700 shsAverage Volume250,452 shsMarket Capitalization$847,800.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get GRI Bio alerts: Email Address Ad Chaikin AnalyticsWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?To see this July stock warning for yourself – 100% free – click here. About GRI Bio Stock (NASDAQ:GRI)GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Read More GRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRI Stock News HeadlinesJuly 2, 2024 | globenewswire.comGRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care MedicineJuly 1, 2024 | globenewswire.comGRI Bio to Present at the 8th Annual IPF SummitJuly 7, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).June 28, 2024 | globenewswire.comGRI Bio Announces Closing of $4.0 Million Public OfferingJune 28, 2024 | americanbankingnews.comGRI Bio, Inc. (NASDAQ:GRI) Short Interest Down 98.2% in JuneJune 27, 2024 | globenewswire.comGRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell ModulatorsJune 26, 2024 | investorplace.comWhy Is GRI Bio (GRI) Stock Down 29% Today?June 14, 2024 | globenewswire.comGRI Bio Announces Reverse Stock SplitJuly 7, 2024 | Stansberry Research (Ad)BUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).May 23, 2024 | finance.yahoo.comGRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO ConnectMay 22, 2024 | globenewswire.comGRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) ProgramsMay 21, 2024 | globenewswire.comGRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)May 20, 2024 | finance.yahoo.comGRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)May 20, 2024 | globenewswire.comGRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)May 15, 2024 | washingtonpost.comZiopharm: Q1 Earnings SnapshotMay 14, 2024 | finance.yahoo.comGRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company ShowcaseMay 14, 2024 | globenewswire.comGRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company ShowcaseMay 13, 2024 | msn.comGRI Stock Earnings: GRI Bio Reported Results for Q1 2024See More Headlines Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/06/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GRI CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-548.12% Return on Assets-290.50% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value5.22 per share Price / Book0.30Miscellaneous Outstanding Shares540,000Free Float528,000Market Cap$847,800.00 OptionableNot Optionable Beta-1.68 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. W. Marc Hertz Ph.D. (Age 53)Co-Founder, CEO, President & Director Comp: $842.01kMs. Leanne M. Kelly (Age 47)CFO & Corporate Secretary Comp: $550.93kDr. Vipin Kumar Chaturvedi Ph.D. (Age 64)Co-Founder & Chief Scientific Officer Dr. Albert Agro Ph.d. (Age 59)Chief Medical Officer Key CompetitorsTRACON PharmaceuticalsNASDAQ:TCONEvoke PharmaNASDAQ:EVOKBio-PathNASDAQ:BPTHProtagenic TherapeuticsNASDAQ:PTIXGenprexNASDAQ:GNPXView All Competitors GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed this year? GRI Bio's stock was trading at 35.04 at the beginning of 2024. Since then, GRI shares have decreased by 95.5% and is now trading at 1.57. View the best growth stocks for 2024 here. How were GRI Bio's earnings last quarter? GRI Bio, Inc. (NASDAQ:GRI) issued its quarterly earnings data on Friday, May, 10th. The company reported ($5.98) earnings per share (EPS) for the quarter. When did GRI Bio's stock split? Shares of GRI Bio reverse split before market open on Tuesday, June 18th 2024. The 1-13 reverse split was announced on Tuesday, June 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRI) was last updated on 7/7/2024 by MarketBeat.com Staff From Our PartnersI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.